Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 200 Medical Plaza, Suite 365C, Los Angeles, CA 90095, USA.
Division of Gastroenterology, NYU Langone Medical Center, 1000 Northern Boulevard, Great Neck, NY 11021, USA.
Nat Rev Gastroenterol Hepatol. 2014 Feb;11(2):128-38. doi: 10.1038/nrgastro.2013.241. Epub 2013 Dec 17.
As the global population ages, the number of older people (≥65 years) living with IBD is expected to increase. IBD therapeutics have advanced considerably over the past few decades with the introduction of multiple steroid-sparing agents as well as numerous clinical trials that have tested new therapeutic targets. However, the current paradigms for IBD management might not be directly translatable to older patients with IBD. Age-related factors such as immunodeficiency relative to younger patients, comorbidity, polypharmacy and diminished physical reserve directly or indirectly affect the natural history of their disease. This Review highlights how these age-associated variables can affect older patients with IBD and also illustrates the multiple gaps in our current knowledge of IBD in the elderly.
随着全球人口老龄化，患有炎症性肠病（IBD）的老年人（≥65 岁）的数量预计将会增加。在过去几十年中，随着多种类固醇保留剂的引入以及大量临床试验测试新的治疗靶点，IBD 的治疗方法已经有了很大的进步。然而，目前的 IBD 管理模式可能无法直接转化为患有 IBD 的老年患者。与年轻患者相比，年龄相关的因素，如免疫缺陷、合并症、多种药物治疗和身体储备减少，直接或间接地影响其疾病的自然病程。本综述强调了这些与年龄相关的变量如何影响患有 IBD 的老年患者，并说明了我们目前对老年 IBD 认识中的多个空白。
